DOI QR코드

DOI QR Code

Synthesis of Reconstituted High Density Lipoprotein (rHDL) Containing apoA-I and apoC-III: the Functional Role of apoC-III in rHDL

  • Cho, Kyung-Hyun (School of Biotechnology, Aging-associated Vascular Disease Research Center, Yeungnam University)
  • Received : 2008.07.03
  • Accepted : 2008.12.16
  • Published : 2009.03.31

Abstract

Apolipoprotein (apo) C-III is a marker protein of triacylglycerol (TG)-rich lipoproteins and high-density lipoproteins (HDL), and has been proposed as a risk factor of coronary heart disease. To compare the physiologic role of reconstituted HDL (rHDL) with or without apoC-III, we synthesized rHDL with molar ratios of apoA-I:apoC-III of 1:0, 1:0.5, 1:1, and 1:2. Increasing the apoC-III content in rHDL produced smaller rHDL particles with a lower number of apoA-I molecules. Furthermore, increasing the molar ratio of apoC-III in rHDL enhanced the surfactant-like properties and the ability to lyse dimyristoyl phosphatidylcholine. Furthermore, rHDL containing apoC-III was found to be more resistant to particle rearrangement in the presence of low-density lipoprotein (LDL) than rHDL that contained apoA-I alone. In addition, the lecithin:cholesterol acyltransferase (LCAT) activation ability was reduced as the apoC-III content of the rHDL increased; however, the CE transfer ability was not decreased by the increase of apoC-III. Finally, rHDL containing apoC-III aggravated the production of MDA in cell culture media, which led to increased cellular uptake of LDL. Thus, the addition of apoC-III to rHDL induced changes in the structural and functional properties of the rHDL, especially in particle size and rearrangement and LCAT activation. These alterations may lead to beneficial functions of HDL, which is involved in anti-atherogenic properties in the circulation.

Acknowledgement

Supported by : Korea Science and Engineering Foundation, Yeungnam University

References

  1. Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Naval, M., and Fogelman, A.M. (2004). Antiinflammatory properties of HDL. Circ. Res. 9, 764-772 https://doi.org/10.1161/01.RES.0000146094.59640.13
  2. Breyer, E.D., Le, N.A., Li, X., Martinson, D., and Brown, W.V. (1999). Apolipoprotein C-III displacement of apolipoprotein E from VLDL:effect of particle size. J. Lipid Res. 40, 1875-1882
  3. Brousseau, M.E. (2005). Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. Drug Discov. Today 10, 1095-1101 https://doi.org/10.1016/S1359-6446(05)03514-2
  4. Brown, M.L., Inazu, A., Hesler, C.B., Agellon, L.B., Mann, C., Whitlock, M.E., Marcel, Y.L., Milne, R.W., Koizumi, J., Mabuchi, H., et al. (1989). Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342, 448-51 https://doi.org/10.1038/342448a0
  5. Bruns, G.A., Karathanasis, S.K., and Breslow, J.L. (1984). Human apolipoprotein A-I--C-III gene complex is located on chromosome 11. Arteriosclerosis 4, 97-102 https://doi.org/10.1161/01.ATV.4.2.97
  6. Cho, K.H., and Jonas, A. (2000). A key point mutation (V156E) affects the structure and functions of human apolipoprotein A-I. J. Biol. ChemK 275, 26821-26827 https://doi.org/10.1074/jbc.M002841200
  7. Cho, K.H., Lee, J.Y., Choi, M.S., Cho, J.M., Lim, J.S., and Park, Y.B.(1998). A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim. Biophys. Acta 30, 133-144 https://doi.org/10.1016/S0005-2760(97)00197-5
  8. Cho, K.H., Shin, D.G., Baek, S.H., and Kim, J.R. (2009). Myocardial infarction patients showed altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp. Mol. Med. 41, 67-76 https://doi.org/10.3858/emm.2009.41.2.009
  9. Ginsberg, H.N., Le, N.A., Goldberg, I.J., Gibson, J.C., Rubinstein, A., Wang-Iverson, P., Norum, R., and Brown, W.V. (1986). Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78, 1287-1295 https://doi.org/10.1172/JCI112713
  10. Ginsberg, H.N., Jones, J., Blaner, W.S., Thomas, A., Karmally, W., Fields, L., Blood, D., and Begg, M.D. (1995). Association of postprandial triglyceride and retinyl plalmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler. Thromb. Vasc. Biol. 15, 1829-1838 https://doi.org/10.1161/01.ATV.15.11.1829
  11. Han, J.M., Jeong, T.S., Lee, W.S., Choi, I., and Cho, K.H. (2005). Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J. Lipid. Res. 46, 589-596 https://doi.org/10.1194/jlr.M400468-JLR200
  12. Hodis, H.N. (1999). Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 99, 2852-2854 https://doi.org/10.1161/01.CIR.99.22.2852
  13. Jonas, A. (1991). Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim. Biophys. Acta 1084, 205-220 https://doi.org/10.1016/0005-2760(91)90062-M
  14. Jonas, A., Sweeny, S.A., and Herber, P.N. (1984). Discoidal complexes of A and C apolipoproteins with lipids and their reactions with lecithin:cholesterol acyltransferase. J. Biol. Chem. 259, 6369-6375
  15. Jonas, A., Kezdy, K.E., and Wald, J.H. (1989). Defined apolipoprotein A-I conformations in reconstituted high density lipoprotein discs. J. Biol. Chem. 264, 4818-4824
  16. Jonas, A., Wald, J.H., Toohill, K.L., Krul, E.S., and Kezdy, K.E. (1990). Apolipoprotein A-I structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. J. Biol. Chem. 265, 22123-22129
  17. Lee, S., Campos, H., Moye, L.A., and Sacks, F.M. (2003). LDL containing apolipoprotein C-III is an independent risk factor for coronary events in diabetic patients. Arterioscler. Thromb. Vasc. Biol. 23, 853-858 https://doi.org/10.1161/01.ATV.0000066131.01313.EB
  18. Lewis, G.F., and Rader, D.J. (2005). New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232 https://doi.org/10.1161/01.RES.0000170946.56981.5c
  19. Markwell, M.A., Haas, S.M., Bieber, L.L., and Tolbert, N.E. (1978). A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. BiochemK 87, 206-210 https://doi.org/10.1016/0003-2697(78)90586-9
  20. Matz, C.E., and Jonas, A. (1982). Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem 257, 4535-4540
  21. Nishida, H.I., Nakanishi, T., Yen, E.A., Arai, H., Yen, F.T., and Nishida, T. (1986). Nature of the enhancement of lecithincholesterol acyltransferase reaction by various apolipoproteins. J. Biol. Chem. 261, 12028-12035
  22. Onat, A., Hergenc, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., and Assmann, G. (2003). Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 168, 81-89 https://doi.org/10.1016/S0021-9150(03)00025-X
  23. Ooi, E.M.M., Barrett, P.H.R., Chan, D.C., and Watts, G.F. (2008). Apolipoprotein C-III:understanding an emerging cardiovascular risk factor. Clin. Sci. 114, 611-624 https://doi.org/10.1042/CS20070308
  24. Park, S.H., Park, J.E., Kim, Y.O., Song, K.J., Kim, S.S., Kim, J.R., Choi, I., Kim, J.J., and Cho, K.H. (2008). Function and composition of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients. Clin. Biochem. 41, 56-64 https://doi.org/10.1016/j.clinbiochem.2007.10.007
  25. Pownall, H.J., Massey, J.B., Kusserow, S.K., and Gotto, A.M., Jr. (1978). Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry 17, 1183-1188 https://doi.org/10.1021/bi00600a008
  26. Sacks, F.M., Alaupovic, P., Moye, L.A., Cole, T.G., Sussex, B., Stampfer, M.J., Pfeffer, M.A., and Braunwald, E. (2000). VLDL, Apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE). Trial. Circulation 102, 1886-1892 https://doi.org/10.1161/01.CIR.102.16.1886
  27. Shachter, N.S. (2001). Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12, 297-304 https://doi.org/10.1097/00041433-200106000-00009
  28. Sparks, D.L., and Pritchard, P.H. (1989). Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apoprotein content. J. Lipid. Res. 30, 1491-1498
  29. Staros, J.V. (1982). N-hydroxysulfosuccinimide active esters: bis Nhydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry 21, 3950-3955 https://doi.org/10.1021/bi00260a008
  30. Ting, H.J., Stice, J.P., Schaff, U.Y., Hui, D.Y., Rutledge, J.C., Knowlton, A.A., Passerini, A.G., and Simon, S.I. (2007). Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ. Res. 100, 381-390 https://doi.org/10.1161/01.RES.0000258023.76515.a3
  31. Wang, C.S., McConathy, W.J., Kloer, H.U., and Alaupovic, P. (1985). Modulation of lipoprotein lipase activity by apolipoproteins. J. Clin. Invest. 75, 384-390 https://doi.org/10.1172/JCI111711